Fly News Breaks for March 4, 2020
Mar 4, 2020 | 12:13 EDT
Arcturus Therapeutics this morning announced a collaboration agreement with Duke-NUS, a partnership between the Duke University School of Medicine and the National University of Singapore, to co-develop a coronavirus vaccine for Singapore, H.C. Wainwright analyst Ed Arce tells investors in a research note. The analyst believes the "unique combination of attributes" leveraged by this collaboration could produce one of the best options for a COVID-19 vaccine. He affirms a Buy rating on Arcturus shares with an $18 price target.
News For ARCT From the Last 2 Days
There are no results for your query ARCT